Mutated Ras genes are found in approximately 30% of all human cancers. For instance, KRAS mutations are prevalent in pancreatic, colorectal, and lung cancers. These mutations contribute to the malignancy by promoting uncontrolled cell division and inhibiting apoptotic pathways, making them a significant target for cancer research and therapeutic interventions.
